IQVIA Holdings Inc. (IQV) Stock Analysis 2026

HealthcareDiagnostics & Research
$275.06
as of 2026-10-29
+40.8% (52-week)50D MA $223.12  |  200D MA $200.99

BriMind AI Score

Proprietary
51
Neutral
Price CAGR
14.5%
1Y Return
+26.7%
Analyst Upside
-1.5%
Rev Growth
8.7%

Score based on historical price CAGR, revenue growth, analyst upside, and valuation factors. Updated daily.

BriMind 1-Year Price Target

$317.44+15.4% potential
Bear Case
$238.89
Bull Case
$368.18
Model Confidence90%

An even blend of the BriMind AI model's DCF and momentum target ($323.40) and Wall Street's consensus target ($311.47).

AI scores and price targets are for informational and educational purposes only. They do not constitute financial advice or a recommendation to buy or sell any security. Past performance is not indicative of future results. Always conduct your own research before making investment decisions. Full Disclaimer →

IQV Revenue & Profitability Breakdown

This chart shows how IQV's revenue flows through to profit. Each row deducts a layer of costs: first the direct cost of making products/services (Cost of Revenue), then operating expenses like marketing and R&D, then taxes. What remains at the bottom is net income — the actual profit shareholders own. High gross and net margins indicate a business with strong pricing power and efficiency.

Revenue
$16.98B
Cost of Revenue
-$11.38B
Gross Profit
$5.60B33.0% margin
Operating Expenses
-$3.39B
Operating Income
$2.21B13.0% margin
Tax & Other
-$837.4M
Net Income
$1.37B8.1% margin
Gross Margin
33.0%
Operating Margin
13.0%
Net Margin
8.1%
EBITDA Margin
18.9%

Key Financial Metrics

IQVIA Holdings Inc. trades at a trailing P/E of 32.56x, generates $2.15B in free cash flow, runs a debt/equity ratio of 257.98, and converts shareholder equity into profit at a 22.8% return on equity. For context: P/E ratio measures how much you pay for $1 of earnings (lower = cheaper, but fast-growing companies command higher P/E); Free Cash Flow is the cash left after running the business; Debt/Equity shows how leveraged a company is; Return on Equity shows how efficiently it turns shareholder capital into profit.

Market Cap
$43.08B
Enterprise Value
$39.02B
P/E (Trailing)
32.56
P/E (Forward)
18.10
PEG Ratio
1.07
EV / EBITDA
13.34
Price / Sales
1.70
Price / Book
4.44
Revenue
$16.98B
Revenue Growth
8.7%
Earnings Growth
-0.6%
EBITDA
$2.93B
Gross Margin
33.0%
Operating Margin
13.0%
Net Margin
8.1%
Return on Equity
22.8%
Return on Assets
5.1%
Free Cash Flow
$2.15B
Total Cash
$1.88B
Total Debt
$14.54B
Debt / Equity
257.98
Current Ratio
0.71
Quick Ratio
0.62
Beta
1.18
Dividend Yield
None
Payout Ratio
0.0%
Insider Ownership
1.1%
Inst. Ownership
103.4%
Short % Float
3.0%
Book Value / Share
$37.49

Wall Street Analyst Consensus

19 analysts covering IQVIA Holdings Inc. currently lean toward a Buy rating, with a mean 12-month price target of $275.17 (+0.0% vs the current price). Analysts set these targets after researching a company's earnings, competitive position, and industry trends — Strong Buy / Buy means the majority expect meaningful upside, while Hold means fair value near the current price rather than a sell signal.

Consensus RatingBuy(19 analysts)
SellStrong Buy
Low Target$160.00-41.8%
Mean Target$275.17+0.0% upside
High Target$268.00+-2.6%

Intrinsic Value Estimates for IQV

We use 1 valuation model to estimate IQV's intrinsic value. Intrinsic value is what a stock is truly worth based on the company's fundamentals, independent of what the market prices it at today. If multiple models agree the stock is undervalued, that convergence is a stronger signal.

DCF Model (10yr)
$260.95
-5.1% vs current
Discounts 10 years of projected free cash flow back to today's dollars (5% growth, 10% discount rate). Best for companies generating consistent cash.
Fair Value Range
$260.95 – $260.95
Average Estimate
$260.95
Potential Downside
-5.1%

Intrinsic value estimates use simplified models (Graham, DCF, P/E) and conservative assumptions. They should be used as one input among many — not as sole buy/sell guidance. For advanced analysis, see the full platform.

Technical Price Signals

IQV is currently in a golden cross pattern, trading above its 50-day average of $223.12 and above its 200-day average of $200.99. Moving averages smooth out day-to-day volatility to reveal the underlying trend — a Golden Cross (50MA crosses above 200MA) is a classic bullish signal, a Death Cross is bearish, though both are lagging indicators that confirm trends rather than predict them.

Current Price
$275.06
50-Day MA
$223.12
▲ Price above
200-Day MA
$200.99
▲ Price above
Golden Cross Pattern
Price above both MAs — bullish signal

Compare IQV with Peers

CRL vs IQVCharles River vs IQVIA — CRO vs Full-Service Research &
IQV vs ICLRIQVIA vs ICON — CRO Giants Compared for Clinical Resear
IQV vs MEDPIQVIA vs Medpace — CRO Giant vs Niche Phase I-IV Specia

Further Reading

Research and guides that put IQV’s numbers in context — how to read the filings behind them, and the frameworks we use to score them.

BeginnerWhat Is an AI Stock Score? How BriMindInvest Ranks StocksMarket TheoryStock Market Seasonality: Monthly Returns, 'Sell in May,' and What History SaysMarket TheoryWe Backtested 929 Insider Cluster Buys — The Signal Everyone Trusts Loses to the S&P 500Fundamentals58% of Insider Selling Is Noise — How to Find the Part That Matters

More Healthcare Stock Analysis

In-depth reports on companies operating alongside IQV — business models, bull and bear cases, and the metrics that matter.

NTRANatera, Inc.Diagnostics & ResearchTMOThermo Fisher Scientific Inc.Diagnostics & ResearchDHRDanaher CorporationDiagnostics & ResearchCAHCardinal Health, Inc.Medical DistributionHUMHumana Inc.Healthcare PlansSYKStryker CorporationMedical DevicesTEMTempus AI, Inc.Health Information ServicesJNJJohnson & JohnsonDrug Manufacturers - General

Unlock the Full IQV Analysis

Interactive price charts, real-time AI signals, advanced DCF models, portfolio tracking, earnings analysis, and side-by-side peer comparisons. Start your 14-day free trial — no credit card required.

Start Free TrialBrowse All Stocks
Data sources: Financial metrics and market data sourced from company SEC filings, earnings releases, and investor relations disclosures. Price data, analyst consensus targets, and fundamental financials provided by financial market data providers. ETF data sourced from official fund prospectuses and index provider publications. AI scores and price targets are proprietary estimates — see our Methodology and Disclaimer for details.
← Back to Home · Browse All Stock Analysis